- Home
- CSGP vs ARGX Comparison
CSGP vs ARGX Comparison
Compare CSGP & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSGP
- ARGX
- Stock Information
- Founded
- CSGP 1987
- ARGX 2008
- Country
- CSGP United States
- ARGX Netherlands
- Employees
- CSGP N/A
- ARGX N/A
- Industry
- CSGP Business Services
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSGP Consumer Discretionary
- ARGX Health Care
- Exchange
- CSGP Nasdaq
- ARGX Nasdaq
- Market Cap
- CSGP 32.2B
- ARGX 37.3B
- IPO Year
- CSGP 1998
- ARGX 2017
- Fundamental
- Price
- CSGP $72.28
- ARGX $627.40
- Analyst Decision
- CSGP Buy
- ARGX Strong Buy
- Analyst Count
- CSGP 13
- ARGX 20
- Target Price
- CSGP $93.00
- ARGX $634.50
- AVG Volume (30 Days)
- CSGP 2.4M
- ARGX 257.3K
- Earning Date
- CSGP 02-18-2025
- ARGX 10-31-2024
- Dividend Yield
- CSGP N/A
- ARGX N/A
- EPS Growth
- CSGP N/A
- ARGX N/A
- EPS
- CSGP 0.43
- ARGX N/A
- Revenue
- CSGP $2,666,900,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- CSGP $13.48
- ARGX $61.99
- Revenue Next Year
- CSGP $12.85
- ARGX $42.48
- P/E Ratio
- CSGP $170.02
- ARGX N/A
- Revenue Growth
- CSGP 11.67
- ARGX 85.56
- 52 Week Low
- CSGP $68.26
- ARGX $349.86
- 52 Week High
- CSGP $100.38
- ARGX $644.97
- Technical
- Relative Strength Index (RSI)
- CSGP 42.57
- ARGX 61.06
- Support Level
- CSGP $71.80
- ARGX $623.78
- Resistance Level
- CSGP $73.52
- ARGX $637.08
- Average True Range (ATR)
- CSGP 2.22
- ARGX 13.21
- MACD
- CSGP -0.38
- ARGX -0.35
- Stochastic Oscillator
- CSGP 32.11
- ARGX 67.96
About CSGP CoStar Group Inc.
CoStar Group is a leading provider of commercial real estate data and marketplace listing platforms. Its data offering contains in-depth analytical information on over 5 million commercial real estate properties related to various subsectors including office, retail, hotels, multifamily, healthcare, industrial, self-storage, and data centers. It operates many flagship brands such as CoStar Suite, LoopNet, Apartments.com, BizBuySell, and Lands of America, with more than 80% of its revenue classified as subscription-based. The company recently expanded its presence in Canada, the United Kingdom, Spain, and France.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.